CR9851A - TRIAZOLOPIRIDINE DERIVATIVES IN QUALITY OF LIPASE AND PHOSPHOLIPASE INHIBITORS - Google Patents

TRIAZOLOPIRIDINE DERIVATIVES IN QUALITY OF LIPASE AND PHOSPHOLIPASE INHIBITORS

Info

Publication number
CR9851A
CR9851A CR9851A CR9851A CR9851A CR 9851 A CR9851 A CR 9851A CR 9851 A CR9851 A CR 9851A CR 9851 A CR9851 A CR 9851A CR 9851 A CR9851 A CR 9851A
Authority
CR
Costa Rica
Prior art keywords
derivatives
triazolopiridine
lipase
quality
phospholipase inhibitors
Prior art date
Application number
CR9851A
Other languages
Spanish (es)
Inventor
Petry Stefan
Zoller Gerhard
Muller Gunter
Baringhaus Karl-Heinz
Heuer Hubert
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CR9851A publication Critical patent/CR9851A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)

Abstract

La invencion se refiere a derivados de triazolopiridina de la formula general (I) que se definen como se cita en la parte descriptiva, a sus sales farmaceuticamente utiles y su uso como sustancias medicinales.The invention relates to triazolopyridine derivatives of the general formula (I) which are defined as cited in the descriptive part, to their pharmaceutically useful salts and their use as medicinal substances.

CR9851A 2005-10-19 2008-03-28 TRIAZOLOPIRIDINE DERIVATIVES IN QUALITY OF LIPASE AND PHOSPHOLIPASE INHIBITORS CR9851A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005049954A DE102005049954A1 (en) 2005-10-19 2005-10-19 Triazolopyridine derivatives as inhibitors of lipases and phospholipases

Publications (1)

Publication Number Publication Date
CR9851A true CR9851A (en) 2008-07-29

Family

ID=37487398

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9851A CR9851A (en) 2005-10-19 2008-03-28 TRIAZOLOPIRIDINE DERIVATIVES IN QUALITY OF LIPASE AND PHOSPHOLIPASE INHIBITORS

Country Status (26)

Country Link
US (2) US7718669B2 (en)
EP (1) EP1940838B1 (en)
JP (1) JP2009512649A (en)
KR (1) KR20080057299A (en)
CN (1) CN101291932A (en)
AR (1) AR058095A1 (en)
AU (1) AU2006303551A1 (en)
BR (1) BRPI0617712A2 (en)
CA (1) CA2625442A1 (en)
CR (1) CR9851A (en)
DE (1) DE102005049954A1 (en)
DO (1) DOP2006000227A (en)
EC (1) ECSP088376A (en)
HN (1) HN2006035237A (en)
IL (1) IL190715A0 (en)
MA (1) MA29857B1 (en)
MY (1) MY140514A (en)
NO (1) NO20082159L (en)
NZ (1) NZ567574A (en)
PE (1) PE20070820A1 (en)
RU (1) RU2008119435A (en)
TN (1) TNSN08178A1 (en)
TW (1) TW200800987A (en)
UY (1) UY29878A1 (en)
WO (1) WO2007045392A1 (en)
ZA (1) ZA200802369B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005049954A1 (en) * 2005-10-19 2007-05-31 Sanofi-Aventis Deutschland Gmbh Triazolopyridine derivatives as inhibitors of lipases and phospholipases
TW200730474A (en) 2005-12-29 2007-08-16 Schering Ag Diamine derivatives as inhibitors of leukotriene A4 hydrolease
FR2915199B1 (en) * 2007-04-18 2010-01-22 Sanofi Aventis TRIAZOLOPYRIDINE-CARBOXAMIDE AND TRIAZOLOPYRIMIDINE-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
FR2915197B1 (en) * 2007-04-18 2009-06-12 Sanofi Aventis Sa TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF.
FR2915198B1 (en) * 2007-04-18 2009-12-18 Sanofi Aventis TRIAZOLOPYRIDINE CARBOXAMIDE AND TRIAZOLOPYRIDINE -CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
EP2351744B1 (en) 2008-10-17 2015-01-07 Shionogi & Co., Ltd. Acetic acid amide derivative having inhibitory activity on vascular endothelial lipase
NZ593418A (en) * 2008-12-24 2013-10-25 Bial Portela & Ca Sa Imidazole compounds for use as enzyme inhibitors
CN102753545A (en) 2009-12-15 2012-10-24 盐野义制药株式会社 Oxadiazole derivative having endothelial lipase inhibitory activity
SG186885A1 (en) 2010-06-04 2013-02-28 Albany Molecular Res Inc Glycine transporter-1 inhibitors, methods of making them, and uses thereof
EP2582709B1 (en) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
ES2864862T3 (en) 2013-03-12 2021-10-14 Celltaxis Llc Leukotriene A4 hydrolase inhibition methods
MX2015011677A (en) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibitors of leukotriene a4 hydrolase.
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
ES2700541T3 (en) 2013-03-14 2019-02-18 Univ Columbia Octahidrociclopentapirroles, its preparation and use
KR20150131211A (en) 2013-03-14 2015-11-24 켈탁시스, 인코퍼레이티드 Inhibitors of leukotriene a4 hydrolase
WO2014152518A2 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
WO2014151959A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
ES2705247T3 (en) 2013-03-14 2019-03-22 Univ Columbia 4-phenylpiperidines, their preparation and use
WO2015061272A1 (en) * 2013-10-22 2015-04-30 Bristol-Myers Squibb Company Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
EP4036094A1 (en) * 2014-04-30 2022-08-03 The Trustees of Columbia University in the City of New York Substituted 4-phenylpiperidines, their preparation and use
KR20190043437A (en) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 Heterocylic compound as a protein kinase inhibitor
WO2019232306A1 (en) 2018-05-31 2019-12-05 Celtaxsys, Inc. Method of reducing pulmonary exacerbations in respiratory disease patients
CN117126134A (en) * 2022-05-20 2023-11-28 中国科学院上海药物研究所 Novel tetrahydroisoquinoline compounds, preparation method thereof, pharmaceutical composition containing compounds and application of compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
DE10247680B4 (en) * 2002-10-12 2005-09-01 Aventis Pharma Deutschland Gmbh New bicyclic inhibitors of the hormone sensitive lipase
DE102004005172A1 (en) * 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazole derivatives as inhibitors of the hormone sensitive lipase
DE102005049954A1 (en) * 2005-10-19 2007-05-31 Sanofi-Aventis Deutschland Gmbh Triazolopyridine derivatives as inhibitors of lipases and phospholipases

Also Published As

Publication number Publication date
MY140514A (en) 2009-12-31
AR058095A1 (en) 2008-01-23
MA29857B1 (en) 2008-10-03
NO20082159L (en) 2008-05-08
WO2007045392A1 (en) 2007-04-26
DOP2006000227A (en) 2007-05-15
AU2006303551A1 (en) 2007-04-26
US20090030011A1 (en) 2009-01-29
BRPI0617712A2 (en) 2011-08-02
US20100190801A1 (en) 2010-07-29
HN2006035237A (en) 2010-03-11
UY29878A1 (en) 2007-05-31
KR20080057299A (en) 2008-06-24
US7718669B2 (en) 2010-05-18
TNSN08178A1 (en) 2009-10-30
NZ567574A (en) 2010-03-26
EP1940838A1 (en) 2008-07-09
ZA200802369B (en) 2009-01-28
EP1940838B1 (en) 2012-08-22
CN101291932A (en) 2008-10-22
DE102005049954A1 (en) 2007-05-31
PE20070820A1 (en) 2007-09-04
ECSP088376A (en) 2008-05-30
RU2008119435A (en) 2009-11-27
IL190715A0 (en) 2008-11-03
JP2009512649A (en) 2009-03-26
CA2625442A1 (en) 2007-04-26
TW200800987A (en) 2008-01-01

Similar Documents

Publication Publication Date Title
CR9851A (en) TRIAZOLOPIRIDINE DERIVATIVES IN QUALITY OF LIPASE AND PHOSPHOLIPASE INHIBITORS
UY29853A1 (en) DERIVATIVES OF DIACILINDAZOL AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES-
ECSP10010246A (en) BETA-LACTAMASA INHIBITORS
ECSP088377A (en) CARBAMOILBENZOTRIAZOL DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES
GT200900292A (en) "KINASE INHIBITORS P70 S6"
UY30498A1 (en) NEW CLASS OF BENZIMIDAZOLILO COMPOUNDS, ITS SALTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS
ECSP077271A (en) PIRIMIDINE DERIVATIVES
UY32203A (en) AMINO PIRIMIDINAS AND ITS USE IN THERAPY
UY32626A (en) BETA-LACTAMASA INHIBITORS
NI200900031A (en) N-METHYLAMINOMETHYL ISOINDOL COMPOSITIONS AND COMPOSITIONS THAT INCLUDE THEM AND METHODS FOR USING THEM.
UY31001A1 (en) IMIDAZOLIDINACARBOXAMIDE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES
ECSP077259A (en) PIRIMIDINE DERIVATIVES
EA200870217A1 (en) 4-Aryl-2-aminopyrimidines or 4-aryl-2-aminoalkylpyrimidines as modulators JAK-2 and containing their pharmaceutical compositions
CR11819A (en) 5-SUBSTITUTED ISOINDOLINE COMPOUNDS
UY31481A1 (en) NEW PIRIMIDINE DERIVATIVES, PREPARATION PROCESSES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS
CU20100123A7 (en) PHARMACEUTICALLY ACCEPTABLE SALTS OF (3 - {[[3- (6-AMINO-2-BUTOXI-8-OXO-7,8-DIHIDRO-9H-PURIN-9-IL) PROPIL] (3-MORFOLIN-4-ILPROPIL) AMINO] METHYL} PHENYL) METHYL ACETATE AND ITS USES IN THERAPY
GT200600117A (en) NEW PHARMACEUTICAL COMPOUNDS
PA8657801A1 (en) TRICYCLE AMINALCOHOLES, PROCEDURES FOR THEIR PREPARATION
CR10206A (en) ACIDS 4-PHENYL-TIAZOL-5-CARBOXYLIC AMIDES OF ACIDS 4-PHENYL-TIAZOL-5-CARBOXYLICS AS INHIBITORS OF THE PLK1
ECSP099442A (en) DERIVATIVES OF HETEROARIL-PIRROLIDINIL- AND -PIPERIDINIL-CETONA
CY1110213T1 (en) AZOLOPYRIDIN-2-ONE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS
UY31000A1 (en) OXOISOXAZOLES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES
UY29594A1 (en) DERIVATIVES OF BENZOTIAZOL-2-ONA AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES
SG162766A1 (en) Benzooxazole-2-on derivatives as lipase and phospholipase inhibitors
CR11391A (en) 1,2,4-TRIAZOL AMINO DERIVATIVES AS MODULATORS OF MGLUR5

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)